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Objective: The objective of this study was to evaluate postapproval outcomes of patients with juxtarenal aortic aneurysms
treated with the Zenith fenestrated endovascular graft (Cook Inc, Bloomington, Ind).
Methods: We reviewed clinical data of consecutive patients treated with the Zenith fenestrated endovascular graft in the
United States at seven institutions with early commercial access from July 2012 to December 2012. Clinical outcomes and
compliance to anatomic guidelines were compared with results of the U.S. fenestrated trial (USFT).
Results: Fifty-seven patients were treated. There were signiﬁcantly more (P < .05) patients with coronary artery disease,
myocardial infarction, and preoperative renal insufﬁciency than in the USFT. Thirty-six patients (63.2%) did not meet the
USFT anatomic criteria of a >4-mm infrarenal neck, and there were signiﬁcantly more mesenteric stents (13 vs 0; P < .05)
used in this group than in the USFT, reﬂecting the higher anatomic complexity of these patients. The total operative time
was 250.2 6 14.8 minutes, the ﬂuoroscopy time was 68.9 6 4.47 minutes, and the average volume of contrast material
was 108.66 5.6 mL. Technical success was 100% in regard to aneurysm exclusion, although the left renal fenestration was
not able to be aligned in two patients, and one patient had a kinked renal stent that was successfully restented. During this
time period, there were a total of 10 endoleaks, of which two were type III and eight were type II.
Conclusions: Despite higher rates of comorbidities and more challenging anatomy, early 30-day outcomes of juxtarenal
aortic aneurysms treated postapproval with the Zenith fenestrated endovascular graft compare well with USFT data.
Future studies are needed to assess durability of this treatment modality as the technology diffuses and data mature.
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(JRAAs) did not exist and therefore the surgical manage-
ment of JRAAs has predominantly remained open surgery
in the United States.1,2 There has been signiﬁcant innova-
tion in the endovascular management of these patients with
techniques including “snorkeling,” chimney grafts, and
custom endografts. However, these rescue and custom
techniques used in elective cases do not uniformly produce
excellent results.3-8 From this clinical need, endovascular
therapy is being developed to treat AAAs with innovate
technologies, allowing the treatment of aneurysms with
maintenance of visceral branch vessel ﬂow. The Zenith
fenestrated device (Cook Inc, Bloomington, Ind) is a de-
vice that can treat AAAs with a short infrarenal neck and
is custom-made with scallops and fenestrations to accom-
modate the branch vessels as needed. The pivotal U.S.
fenestrated trial (USFT) revealed excellent outcomes and
resulted in FDA approval of the device.9 The purpose of
our study was to review the outcomes of the device in
routine clinical use without the limitations of trial inclusion
criteria.
METHODS
Patient selection. A retrospective review was per-
formed of all patients with the diagnosis of AAA undergo-
ing endovascular repair with the Zenith fenestrated
endovascular graft (zFEN) from July 1, 2012, through295
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in the United States: Washington University, St. Louis,
Mo; Indiana University, Indianapolis, Ind; New York Uni-
versity, New York, NY; University of North Carolina,
Chapel Hill, NC; Stanford University, Palo Alto, Calif; Uni-
versity of Pennsylvania, Philadelphia, Pa; and Mayo Clinic,
Rochester, Minn. Institutional review board approval was
gained as required by each institution. The diagnosis of
AAA was made on the basis of radiologic review of preoper-
ative imaging, which was most often computed tomography
(CT) angiography or, alternatively, magnetic resonance
angiography.
The patient’s imaging was used to create a customized
layout for the fenestrated device, which was reviewed by
Cook Inc before production of the device. In the planning
stages, there are several important considerations outlined
in Cook’s instructions for use: the access vessels must be
able to accommodate a 14F to 22F sheath; aortic angulation
from the suprarenal to the infrarenal neck or the infraneck to
the main aortic axis should not exceed 45 degrees; the
infrarenal aortic neck should be at least 4 mm; and there
should not be more than a 10% increase in the diameter of
the aortic neck through the intended seal zone. In addition,
there are limitations on the conﬁgurations: a maximum of
three fenestrations (only two can be of the same size) or a
maximum of two fenestrations with a single scallop.
Procedure. Each operator reviewed preoperative high-
resolution imaging and ordered a graft that was then
manufactured by the company. Devices were implanted
with techniques similar to those of the USFT. Percuta-
neous or open femoral access as well as the choice of renal
or visceral stent implantation was at the discretion of the
operator. All operators used Atrium’s iCAST stent (Atrium
Medical, Hudson NH) for branch vessel stenting. After
implantation of the proximal fenestrated component, the
bifurcated main body and limbs were placed as in a stan-
dard endovascular aneurysm repair. All components were
molded, and completion angiography was performed if it
was deemed necessary. Postoperative antiplatelet therapy
regimens varied and included the following: aspirin only;
aspirin and clopidogrel indeﬁnitely; aspirin and clopidogrel
(only 1 month); and aspirin and clopidogrel (3 months).
Surveillance and imaging protocol. Whereas the spe-
ciﬁc surveillance and imaging protocol strategies were left to
the discretion of the treating physician, all patients were
admitted to the hospital after the procedure and had nonin-
vasive imaging at the time of follow-up. The timing and use
of imaging at follow-up were left to the discretion of each
treating physician. Standard 1-month follow-up should
include an ofﬁce visit and a three-phase CT scan. If there is
no evidence of endoleak, yearly follow-up with repeated CT
scans is sufﬁcient. However, if there is an endoleak, the scan
should be repeated in 3 to 6 months to assess the need for
reintervention. Currently, there is no consensus on the
routine use of duplex ultrasonography to assess branch
vessel stent grafts in this setting. In addition, magnetic
resonance cannot be used to image patients as the branch
vessel stent grafts are constructed with steel.Analysis. Medical records were reviewed, and patient-
speciﬁc information including demographics, vascular
vessel measurements, preoperative variables, postoperative
variables, operative details, and clinical data were extracted.
We excluded patients who did not undergo repair of AAA
with zFEN. Statistical analysis was performed by the un-
paired, two-tailed t-test and Fisher’s exact test.
RESULTS
During the 6-month study period, 57 consecutive pa-
tients underwent endovascular repair of JRAAs with
zFEN and were included for review in comparison to pa-
tients in the USFT. Table I summarizes preoperative and
intraoperative variables. The deﬁnition of each of the vari-
ables was at the discretion of the treating physician. The
mean age of patients was 73.3 years in this study compared
with 75.3 years in the USFT (P ¼ .76). There were 46 men
(86.8%) in this study compared with 33 (78.6%) in the
USFT (P ¼ .81) There were signiﬁcantly more (P < .05)
patients with coronary artery disease, myocardial infarction,
congestive heart failure, and preoperative renal insufﬁ-
ciency than in the USFT (Table I).
The average maximal aneurysm diameter was 60.6 mm
(standard error of the mean [SEM], 6 1.4). The average
aortic diameter at the celiac artery was 26.1 mm (SEM,
6 0.42); at the superior mesenteric artery (SMA),
24.4 mm (SEM, 6 0.48); and at the lowest renal artery,
26.0 mm (SEM, 6 0.98). The average neck diameter
was 26.2 mm (SEM, 6 0.57). The aortic neck length
was deﬁned as the distance from the lowest renal artery
to the beginning of the aneurysm. The average neck length
was 3.47 mm (SEM, 6 0.47). Thirty-six patients (63.2%)
did not meet the USFT anatomic criteria of a >4-mm
infrarenal neck. Therefore, the graft conﬁgurations were
more complex. The most common graft conﬁguration
was used in 36 patients (63%). This was a scallop for the
SMA and bilateral renal artery fenestrations. Eight patients
(14%) had only bilateral renal artery fenestrations. Five pa-
tients (8.8%) had three fenestrations for the SMA and bilat-
eral renal arteries. Two patients (3.5%) had left renal artery
fenestrations only. The following conﬁgurations were each
used once: celiac scallop with SMA and bilateral renal ar-
tery fenestrations, right accessory renal artery fenestration,
right renal artery fenestration only, right renal artery scallop
with a left renal artery fenestration, SMA and right renal ar-
tery fenestration, and SMA scallop with a left renal artery
fenestration. Thirteen patients underwent mesenteric artery
stenting compared with none in the USFT. Of these, two
were celiac stents and 11 were SMA stents (Table II).
All cases were performed on an elective basis; however,
three patients were treated because of the rate of enlarge-
ment (>5 mm in 6 months). The total operative time
was 250.2 minutes (614.8), the ﬂuoroscopy time was
68.9 minutes (64.47), and the average volume of contrast
material was 108.6 mL (65.6). Aneurysm exclusion was
achieved in 100% of the cases as veriﬁed by completion
angiography. The average estimated blood loss was
543.5 mL 6 116.1 (SEM). The majority of patients did
Table II. Presenting anatomic dimensions and intraoperative variables
Study patients (n ¼ 57) zFEN trial patients (n ¼ 42)a P value
Diameter at celiac artery, mm 6 SEM 26.1 6 0.42 28.2 6 3.2 .45
Diameter at SMA, mm 6 SEM 24.4 6 0.48 28 6 3.5 .24
Diameter at lowest patent renal artery, mm 6 SEM 26.0 6 0.98 25.7 6 3.2 .92
Maximum aortic diameter, mm 6 SEM 60.6 6 1.4 61.1 6 10.9 .96
Average neck length,b mm 6 SEM 3.47 6 0.47 4.0c
Vessel stenting
Celiac 2 0
SMA 11 0
Right renal 55 38
Left renal 52 40
AAA, Abdominal aortic aneurysm; SEM, standard error of the mean; SMA, superior mesenteric artery; zFEN, Zenith fenestrated endovascular graft.
ahttps://www.cookmedical.com/zenith/fenestrated/resources/IFUFU%20%20Zenith%20Fenestrated%20AAA%20Endovascular%20Graft%20-%20US.pdf.
bDistance from the lowest renal artery to the beginning of the AAA.
cStudy participation required a minimum of a 4-mm neck.
Table I. Patient demographics
Preoperative variables Study patients (n ¼ 57) zFEN trial patients (n ¼ 42)a P value
Age, years 73.3 75.3 .76
Male 46 (86.8) 33 (78.6) .81
Coronary artery disease 45 (79) 22 (52.4) <.05
Myocardial infarction 34 (59.6) 10 (23.8) <.05
Chronic obstructive pulmonary disease 21 (36.8) 14 (33.3) .83
Renal insufﬁciency 15 (26.3) 4 (9.5) <.05
Diagnosis of congestive heart failure 25 (44) 4 (9.5) <.05
Diagnosis of cardiac arrhythmia 13 (22.8) 17 (40.5) .077
Peripheral vascular disease 23 (40.4) 10 (23.8) .13
Hypertension 56 (98) 39 (92.9) .31
Preoperative renal failure requiring hemodialysis 0 (0) 0 (0) 0
Diabetes 10 (17.5) 11 (26.2) .33
Diagnosis of cerebrovascular disease 8 (14.0) 7 (16.7) .78
Smoking history
Never smoked 4 (7.0) 6 (14.3) .32
Quit smoking 36 (63.2) 24 (57.1) .86
Actively smoker 17 (29.8) 12 (28.6) 1.0
Body mass indexb 29.4 6 4.39 (21.5-40) 28.7 6 4.8 (19.5-40.8) .92
zFEN, Zenith fenestrated endovascular graft.
Data are presented as number (%) unless otherwise indicated.
ahttps://www.cookmedical.com/zenith/fenestrated/resources/IFUFU%20%20Zenith%20Fenestrated%20AAA%20Endovascular%20Graft%20-%20US.pdf.
bBody mass index calculated by height (m2)/weight (kg), mean values 6 standard deviation.
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posures. Ten patients (18%) had percutaneous access for
the main body, and nine patients (16%) had percutaneous
access for the contralateral limb. In one case, the contralat-
eral limb was deployed outside of the distal main body.
This was successfully corrected with placement of a right
aorto-unibody graft, a right to left femoral-femoral bypass,
and an iliac occluder plug in the malpositioned left iliac
limb. Five concomitant procedures were performed,
including right common femoral artery interposition graft
(one), iliac conduits (two), treatment of right iliac artery
aneurysm with embolization and endovascular exclusion
(one), and celiac artery stent to treat an angiographic crit-
ical stenosis (one).
The mean length of stay was 4.33 days (60.43, SEM).
There were three patients (5.3%) in whom the surgeon was
unable to align the left renal fenestration, resulting incoverage of the oriﬁce of the left renal artery by the graft.
In those three cases, the left kidney remained devascular-
ized. The average discharge creatinine concentration for
those patients was 1.19 mg/dL (60.09, SEM) with a
range of 1.1 to 1.3 mg/dL, and none of those patients
needed short- or long-term hemodialysis. In addition,
none of those patients had immediate or late endoleaks.
There was one mortality during the study period. The pa-
tient was a 77-year-old man who had had a prior aneurysm
repair with an AneuRx device (Medtronic, Santa Rosa,
Calif). The device had migrated inferiorly and was severely
angulated with multiple kinks. The patient, during routine
follow-up, was noted to have developed a 9-cm juxtarenal
aneurysm. The zFEN procedure was technically chal-
lenging and complex and involved bilateral renal artery
stenting, SMA stenting, and bilateral stents at the aortic
bifurcation. The procedure was 608 minutes, with
Table III. Thirty-day outcomes
Study
patients
zFEN trial
patientsa P value
Technical success 57 (100) 42 (100) 1.00
All-cause mortality 1 (1.75) 0 (0) 1.00
AAA-related mortality 0 (0) 0 (0) 1.0
Rupture 0 (0) 0 (0) 1.0
Conversion 0 (0) 0 (0) 1.0
Renal insufﬁciency 4 (7.02) 0 (0) .13
Postoperative dialysis 1 (1.75) 0 (0) 1.00
Migration 0 (0) 0 (0) 1.0
Fenestration stent fracture 0 (0) 0 (0) 1.0
Myocardial infarction 0 (0) 0 (0) 1.0
Paralysis 1 (1.75) 0 (0) 1.0
Stroke 1 (1.75) 0 (0) 1.0
Wound complications 0 (0) 1 (2.44) .42
Renal 1 (1.75) 0 (0) 1.0
Limb occlusion 0 (0) 0 (0) 1.0
Endoleak 10 (17.5) 9 (21.4) .62
Total 10 9
Type I proximal 0 0
Type I distal 0 0
Type II 8 9
Type III 2 0
Type IV 0 0
Unknown 0 0
Reintervention 2 1 1.0
AAA, Abdominal aortic aneurysm; zFEN, Zenith fenestrated endovascular
graft.
Data are presented as number (%).
ahttps://www.cookmedical.com/zenith/fenestrated/resources/IFUFU%
20%20Zenith%20Fenestrated%20AAA%20Endovascular%20Graft%20-%
20US.pdf.
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blood loss. The procedure was a technical success, but
the patient developed multiorgan failure and died on post-
operative day 2. One patient had postoperative pneumonia.
Four patients had a postoperative dysrhythmia, and four
patients had postoperative acute renal failure that did not
require hemodialysis. Of the patients with acute renal fail-
ure, one patient required hemodialysis, and that was the
patient who ultimately died. The average change in creati-
nine concentration for the other three patients was
0.50 mg/dL (60.27, SEM), with a range of 0.6 to
0.9 mg/dL. There were no reported visceral stent throm-
boses, limb occlusions, myocardial infarctions, strokes, or
wound complications.
The average length of follow-up was 52.7 days
(66.17, SEM; range, 2-193 days) in 50 patients. At
follow-up, there were no reported wound complications,
renal or visceral stent thromboses, or limb occlusions.
One patient was noted to have had a myocardial infarc-
tion, and one patient was noted to have had a stroke.
In addition, one patient had a kinked renal artery stent
requiring reintervention with successful additional stent
placement on the second postoperative day. During the
study time, 10 endoleaks were reported. Eight patients
(14%) had type II endoleaks, and two patients (3.5%)
had type III endoleaks. Both type III endoleaks were be-
tween the proximal main body and the renal fenestration.
One was treated with restenting through the existing
renal artery stent; the other was treated with angioplasty
of the renal artery stent, the fenestrated component, and
additional remolding. There were a total of 120 visceral
vessels to be treated, with 117 successfully treated, result-
ing in an immediate target vessel patency of 97.5%
(Table III).
DISCUSSION
A signiﬁcant portion of patients with infrarenal AAAs
have aortic neck anatomy that makes them unsuitable for
traditional endovascular aneurysm repair.10 The operative
management of JRAAs is challenging through the tradi-
tional open or endovascular approach. There are currently
no randomized studies to compare outcomes from open
and endovascular treatment. A study comparing grouped
endovascular and open surgical series revealed an increased
mortality of 2% for open repair.11
Early techniques to treat these aneurysms relied on in-
ventive approaches heralded by skilled physicians. From the
ﬁrst reports published in 1999 to early small series on the
treatment of AAAs with fenestrated grafts, the feasibility
was proved.12-15 In 2004, multiple studies were published
that revealed a promising initial experience with zFEN.
These initial studies had 18 to 32 patients and a 4.5% to
6.5% early endoleak rate with a total of three deaths.16-18
Over time, experience with zFEN increased, and multiple
published studies showed a high technical success rate,
but they did reveal the potential for a signiﬁcant rate
of endoleaks, major complications, and a potential need
for conversion to open repair.19-24 The USFT providedexcellent data on the ability of zFEN to treat JRAAs, and
it was approved for use in April 2012. zFEN is the ﬁrst
FDA-approved graft, and we intended to review the early
postapproval outcomes.
The primary goal of aneurysm repair is aneurysm exclu-
sion, which was accomplished in 100% of the 57 patients in
this series. However, these cases were technically chal-
lenging as many did not have a 4-mm or greater infrarenal
neck as required in the USFT. This resulted in more com-
plex graft conﬁgurations, and, in this study, scallops that
were at risk for minimal misalignment and visceral fenestra-
tions were stented.
In this series, three left renal fenestrations were unable
to be aligned, resulting in loss of perfusion to a kidney in
each case, but none of those patients required hemodialy-
sis. One patient who had acute renal failure was found to
have a thrombosed renal stent secondary to kinking of
that stent. The patient underwent reintervention with suc-
cessful restenting of that renal stent and has had no long-
term sequelae to date. There were a number of early endo-
leaks, eight were type II and only two were type III. One
type III endoleak was noticed on completion angiography
and resolved with remolding of a renal stent to the fenes-
trated graft junction. The other type III endoleak was suc-
cessfully treated with restenting of a renal artery stent. The
remaining patients with type II endoleaks are being
observed and will be treated if it is clinically appropriate.
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learned that there can come a point in cases of this level
of complexity at which the desired outcome cannot be
achieved and persistence to achieve technical success can
result in demise of the patient. Speciﬁcally in this case,
the patient did not tolerate the length of the procedure
and blood loss and developed multisystem organ failure.
The treatment of JRAAs with zFEN requires signiﬁcant
preoperative planning with high-resolution preoperative
imaging. As many other authors have discussed, there are
unique considerations to the implantation of a fenestrated
device.16,17,19,20 Vascular access must be suitable to accom-
modate a fenestrated device, and an iliac conduit may be
needed for this reason. In addition, one must carefully
plan and measure the location and size of visceral and renal
vessels to design the graft. A minimally misaligned scallop
or fenestration could result in the need for unanticipated
stent placement or loss of a vessel. Furthermore, appro-
priate alignment may require signiﬁcant rotation of the
graft in the aortic neck. This raises at least two issues,
including the risk of embolism from thrombus in the
neck and the possibility that the neck may not be large
enough to allow adequate rotation. Once the fenestrated
components are in place, molding must be done perfectly
to avoid type III endoleaks and to maintain visceral and
renal vessel patency. After placement of the fenestrated
portion, the remainder of the procedure has to be per-
formed without disruption of the fenestrated component
and its branches.
One ﬁnal point is simple logistics. These grafts can take
6 weeks to be constructed. Thus, patients who are symp-
tomatic, emergent, or urgent or have AAAs that have signs
concerning for impending rupture should not be candi-
dates. An increasing number of off-the-shelf options are be-
ing developed to accommodate those patients. Experience
with these is limited but growing, and it will be interesting
to see how these perform not only in the emergent setting
but electively in comparison to zFEN.25-27
As this technology diffuses and its application is left
to the discretion of the treating physicians, signiﬁcant is-
sues may arise. There will undoubtedly be a learning
curve for device implantation that involves not only pro-
cedural techniques but preoperative and postoperative
management. As an example, in this study, one patient’s
renal vessel patency was rescued as acute renal failure was
diagnosed early; appropriate imaging was available and
performed, and the correct reintervention was completed
in a timely fashion. Physicians will need to learn the pre-
operative anatomic factors that may make cases chal-
lenging and to make appropriate plans to ensure
excellent outcomes. Long-term success will likely be
found to be dependent on selection of the proper neck
and on assessment of the ability to stent diseased branch
vessels. Ideally, hospitals performing these procedures are
equipped with the necessary diagnostic and interventional
capabilities to rescue patients from complications. It is
unclear at this time if outcomes for zFEN implantation
will correlate to surgeon volume or hospital volume. Inaddition, we do not know how the device will perform
in the short, mid, and long term in patients with aortic
anatomy more complex than reported in this and the
other cited studies.
The long-term results of open repair of AAAs are well
known. The natural history of the aorta proximal to the
repair and the modalities of treatment failure have been
studied. Large centers have repeatedly reported excellent
outcomes. For zFEN to become an accepted treatment
modality, it too must have excellent long-term treatment
outcomes. Although there are short-term and mid-term re-
sults, long-term results are currently lacking. Future studies
will need to report on graft performance over time in re-
gard to continued aneurysm exclusion, but there are also
unique modes of failure for which we will need to acquire
data. Speciﬁcally, even minimal device migration could
result in kinking of visceral or renal stents and loss of perfu-
sion to the viscera or kidneys. The long-term complications
of the variety of stents placed in the celiac artery, SMA, and
renal arteries need to be examined in this speciﬁc context as
well as in regard to the development of endoleaks. It will
also be interesting to gain an understanding of how the
proximal neck will behave over time and if late type Ia
endoleaks will develop.
There are several limitations to this study. As noted
before, the majority of investigators are highly experienced
and skilled endovascular surgeons. Thus, their excellent
outcomes may be reﬂective of this skill and may not trans-
late broadly. In addition, the data have limited follow-up,
and ultimately we will need to know the durability of this
treatment over years. Furthermore, this was not a random-
ized trial, and therefore one cannot exclude selection bias
in the choice of patients for endovascular repair. The deci-
sion between open and endovascular repair of JRAAs was
at the discretion of the treating physician and involved fac-
tors such as the patient’s preference, the patient’s willing-
ness for long-term follow-up with CT, anatomy suitable
for zFEN, a clinical situation appropriate for a wait of 4
to 6 weeks, and the patient’s ability to tolerate an open
operation. Also, all of these cases were performed in a
controlled, elective setting, and therefore one cannot
draw any conclusions about the performance of zFEN in
emergent settings assuming a stock of premade grafts
were to be made available.
CONCLUSIONS
The results of this study highlight excellent early out-
comes of JRAAs treated with zFEN by experienced physi-
cians. This technology will provide physicians with a safe,
effective endovascular therapeutic option for complex
patients with complex aortic disease. Going forward, we
need to analyze long-term outcomes of these patients
and assess how the device performs across varied levels of
physician experience and patient complexity.
The authors acknowledge Dr R. Vallabhaneni for his
work with data collection and data interpretation and assis-
tance with critical revisions.
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